Understanding Mitral Regurgitation

Mitral regurgitation occurs when the mitral valve fails to coapt properly during left ventricular systole, allowing blood to flow retrograde into the left atrium. This creates a volume overload state where the left ventricle must accommodate both systemic venous return and the regurgitant fraction each cardiac cycle. Over time, eccentric hypertrophy and chamber dilation develop as compensatory mechanisms.

Regurgitant severity ranges from trace (clinically insignificant) to massive (requiring urgent intervention). The pathophysiological consequence depends on both the lesion orifice area and the driving pressure gradient across the incompetent valve. Acute severe regurgitation may precipitate flash pulmonary edema and haemodynamic collapse, whereas chronic lesions often remain asymptomatic until late-stage decompensation occurs.

Primary (organic) mitral regurgitation stems from valve apparatus pathology—endocarditis, rheumatic damage, degenerative prolapse, or connective tissue disease. Secondary (functional) regurgitation arises from left ventricular dilation and annular enlargement without intrinsic valve disease, commonly following myocardial infarction or non-ischaemic cardiomyopathy.

EROA Calculation Method

The effective regurgitant orifice area quantifies the anatomical lesion size using continuous-wave doppler and PISA measurement. This approach provides superior reproducibility compared with qualitative colour-flow imaging and integrates haemodynamic principles into a single numeric parameter.

The calculation proceeds in two steps: first, volume flow rate through the PISA surface, then division by peak regurgitant velocity to yield orifice area.

VFR = 2π × r² × Va

EROA = VFR ÷ Vmax

Regurgitant Volume = EROA × VTI

  • r — Radius of the proximal isovelocity surface area hemisphere, measured in centimetres from the colour-flow reversal point to the valve orifice
  • Va — Aliasing velocity (nyquist limit), typically 50–60 cm/s on standard settings, at which the colour map wraps from blue to red
  • Vmax — Peak continuous-wave doppler velocity of the regurgitant jet, measured in centimetres per second
  • VTI — Velocity time integral of the regurgitant jet envelope, obtained by planimetry of the continuous-wave spectral display
  • VFR — Volume flow rate across the PISA surface in millilitres per second

ECHO Acquisition and Measurement Technique

Accurate EROA determination requires meticulous echocardiographic technique. Standardised apical windows—four-chamber, two-chamber, and long-axis views—permit optimal alignment of continuous-wave doppler parallel to regurgitant jet flow. Deviation from parallel incidence introduces cosine error and systematically underestimates velocity.

PISA radius measurement demands colour-flow optimisation. Reduce the nyquist limit until a clear aliasing boundary appears just proximal to the mitral orifice; avoid excessive colour gain, which obscures the reversal zone. Measurement at end-systole minimises variability, though some operators measure at the point of maximum radius.

Continuous-wave tracings should display a full spectral envelope with distinct borders. Incomplete or serrated boundaries suggest suboptimal beam alignment. Multiple cardiac cycles should be averaged, and at least three measurements per parameter should be recorded to account for beat-to-beat variation, particularly in atrial fibrillation.

Validation against surgical or catheterisation data confirms EROA reliability in moderate-to-severe lesions; however, in mild regurgitation, acoustic dropout and measurement noise produce wide confidence intervals.

Common Pitfalls and Caveats

Echocardiographic measurement errors propagate significantly through EROA formulae, particularly the PISA radius which is squared in the volume flow calculation.

  1. Radius measurement variability — The PISA radius must be perpendicular to the regurgitant jet axis. Off-axis measurement or inclusion of colour aliasing artefacts inflates the radius squared term, potentially doubling calculated EROA. Always acquire multiple diameter measurements in orthogonal planes and average them.
  2. Regurgitant jet geometry assumptions — The calculation assumes a hemispherical PISA surface. Eccentric jets or wall-constraining regurgitation violate this assumption and yield overestimated EROA values. Three-dimensional echocardiography may improve accuracy in these complex anatomies.
  3. Timing and loading conditions — Regurgitant severity fluctuates with heart rate, blood pressure, and contractility. Measurements obtained during hypotension or poor contractile function underestimate true lesion severity. Repeat assessment under standardised loading conditions when haemodynamics are stable.
  4. Coexistent valvular disease — Aortic regurgitation or mitral stenosis alters doppler profiles and invalidates single-orifice assumptions. Comprehensive assessment of all four cardiac valves is essential before assigning EROA-based severity grades.

Severity Grading and Clinical Integration

The 2014 ACC/AHA guidelines stratify mitral regurgitation into stages incorporating symptoms, structural valve changes, and quantitative indices including EROA. Asymptomatic primary regurgitation is classified as severe if EROA exceeds 40 mm² or regurgitant volume surpasses 60 mL per beat. Symptomatic lesions are automatically categorised as severe regardless of quantitative values, reflecting the clinical principle that symptom burden mandates intervention.

Secondary (functional) regurgitation follows a separate pathway; mild-to-moderate lesions are conservatively managed with heart failure medications, whereas severe secondary regurgitation with EROA >20 mm² may warrant combined mitral valve and left ventricular remodelling procedures.

Serial echocardiography at 6–12 month intervals provides progression rate and identifies inflection points where medical therapy yields to surgical consideration. Watchful observation remains appropriate for asymptomatic primary lesions with EROA 20–40 mm²; however, repeat imaging is mandatory for borderline values or if symptoms emerge between scheduled assessments.

Frequently Asked Questions

What distinguishes primary from secondary mitral regurgitation in EROA assessment?

Primary mitral regurgitation results from organic valve pathology—endocarditis, prolapse, rheumatic disease—and often progresses insidiously despite stable echocardiographic findings over years. Secondary regurgitation develops from global left ventricular dilation and annular enlargement without structural valve defects; EROA may improve with aggressive heart failure therapy and restoration of left ventricular dimensions. Clinical prognosis and surgical decision-making differ substantially: primary lesions with EROA >40 mm² typically require valve repair or replacement, whereas secondary regurgitation is managed medically unless EROA exceeds 20 mm² plus severe symptoms.

How often should EROA be remeasured in asymptomatic patients?

Asymptomatic severe primary mitral regurgitation warrants echocardiography every 6–12 months to detect left ventricular dilatation, declining ejection fraction, or pulmonary hypertension—any of which triggers surgical consideration before irreversible dysfunction occurs. Asymptomatic mild-to-moderate lesions (EROA 20–40 mm²) require annual assessment. Secondary regurgitation in heart failure patients should be reassessed following guideline-directed medical therapy optimisation; significant EROA reduction suggests functional improvement and defers surgery. Changes in symptoms, exercise tolerance, or clinical status warrant imaging regardless of scheduled intervals.

Why does PISA measurement matter so much in EROA calculation?

The PISA radius term is squared in the volume flow rate formula, meaning a 10% measurement error propagates as a 21% error in final EROA. This amplification makes PISA acquisition the highest-leverage step in the calculation. Echocardiographers must employ multiple orthogonal measurements, optimise colour settings to clearly delineate the aliasing boundary, and average values across multiple cycles to minimise noise. Validation studies confirm EROA reproducibility improves substantially when rigorous PISA technique is employed compared with operator-dependent colour-flow estimation methods.

Can EROA be calculated if the patient has atrial fibrillation?

Yes, but with caveats. Atrial fibrillation introduces beat-to-beat variability in regurgitant volume due to irregular R-R intervals and variable pre-load. EROA itself—the fixed orifice anatomical size—remains constant, but measurement scatter increases. Acquire 5–10 cardiac cycles of continuous-wave doppler and PISA imaging, then average all parameters before calculation. If cycles vary significantly (>15–20%), repeat measurements during periods of relatively regular ventricular response, or note the high measurement uncertainty in the report.

What is the relationship between EROA and regurgitant volume?

Regurgitant volume (mL per beat) equals EROA (cm²) multiplied by the regurgitant jet velocity time integral (cm), converting orifice area into a volume-based severity metric. A patient with EROA 30 mm² and VTI 50 cm yields regurgitant volume of 15 mL—considered mild. The same EROA with VTI 100 cm produces 30 mL—moderate. Both EROA and regurgitant volume are required for severity grading; neither alone is sufficient. Regurgitant volume is particularly useful clinically because it quantifies the actual backward flow burden on the left atrium, whereas EROA reflects pure orifice geometry.

Does the PISA-derived EROA agree with 3D echocardiography measurements?

2D PISA-derived EROA correlates well with 3D echo direct orifice planimetry (R = 0.8–0.9) in most lesions, but systematic bias exists: PISA tends to underestimate EROA in eccentric jets where the hemispherical assumption breaks down, particularly in secondary or posterior-directed regurgitation. 3D planimetry visualises the true anatomical orifice directly, avoiding geometric assumptions, and is increasingly recommended when PISA-derived EROA yields borderline severity grades or when jet eccentricity is evident on 2D imaging. If both methods are available, integration of findings strengthens clinical confidence.

More health calculators (see all)